NVS Earnings

NVS reported its earnings on 2026-02-04, showcasing a revenue of 13.34B against an estimate of 13.72B, resulting in a -2.8% surprise. The EPS was 2.03, surpassing the expected 1.99 by 2.01%. The stock experienced a 2.04% price change on the earnings day and a 4.8% change over the next five days, reflecting market reactions to the results.

Following NVS's earnings announcement on 2026-02-04, the stock price moved by 2.04% on the day of the release. Over the subsequent five days, it saw a 4.8% change. Historically, NVS's stock price tends to shift by an average of 1.01% in the 10 days leading up to earnings and 0.3% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate NVS's annual revenue to reach 13.60B, while the EPS is projected at 1.95. These estimates reflect recent revisions, with revenue estimates revised upward by 0.32% and EPS estimates revised upward by 1.16% over the past three months, indicating analyst expectation in the company's performance.

The correlation between NVS's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were revised upward by 0.32%, while EPS estimates moved revised upward by 1.16%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, NVS's stock price typically moves by 1.01% in the 10 days before its earnings and 0.3% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of 1.95 and revenue of 13.60B.

The earnings call summary and Q&A reveal strong financial performance, growth in key products, and strategic market expansion. Despite some uncertainties, management's optimistic guidance and robust pipeline, including new drug approvals and market opportunities, indicate positive sentiment. The announced growth in free cash flow and strategic focus on oncology and global launches further bolster confidence. Adjustments in the HORIZON trial timeline and management's evasive responses slightly temper the outlook, but overall, the sentiment remains positive, suggesting a likely stock price increase of 2% to 8% over the next two weeks.